Xlr3b Inhibitors
Xlr3b inhibitors are part of a sophisticated class of chemical compounds engineered to selectively target the Xlr3b protein, a critical component within certain cellular pathways. The function of the Xlr3b protein, within its family of proteins, is integral to various molecular processes. The specificity of these inhibitors towards the Xlr3b protein is achieved through a deep understanding of its role at the molecular level. The design of such inhibitors involves identifying the active sites of the Xlr3b protein and developing molecules that can bind to these specific sites effectively. This selective binding is characterized by a high affinity interaction, which can alter the normal function of the Xlr3b protein by modulating its activity.
Creating Xlr3b inhibitors encompasses a multifaceted approach beginning with the elucidation of the protein's involvement in cellular mechanisms and extending to the determination of its three-dimensional structure. Identifying crucial amino acids within the protein that are essential for its activity is a critical step in this process. By combining the expertise of chemists and molecular biologists, molecules are crafted to interact with the Xlr3b protein in a precise manner. These inhibitors often contain complex heterocyclic structures with specific functional groups designed to engage with active sites on the protein. The design process is meticulous, ensuring that the inhibitors are highly selective to reduce nonspecific interactions. Techniques such as X-ray crystallography, computational modeling, and structure-activity relationship studies are pivotal in the refinement of these inhibitors, leading to the precise modulation of the protein's function through structural and chemical innovation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Etoposide is a topoisomerase II inhibitor that leads to DNA damage by preventing the religation of DNA strands. Xlr3b is implicated in DNA repair processes, so etoposide's action would indirectly inhibit Xlr3b by accumulating DNA damage that Xlr3b may not be able to effectively repair. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor that reduces DNA methylation. As methylation can affect gene expression, this could lead to the reduced expression of genes involved in pathways that Xlr3b is a part of, thus indirectly inhibiting Xlr3b's function. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that alters chromatin structure and gene expression. By affecting transcriptional regulation, it may decrease the expression of genes whose products are necessary for Xlr3b activity, thereby inhibiting Xlr3b indirectly. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Paclitaxel stabilizes microtubules and inhibits their disassembly, which can lead to cell cycle arrest. If Xlr3b is involved in cell cycle progression, this cell cycle arrest could indirectly inhibit the functional activity of Xlr3b. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the PI3K/Akt signaling pathway. If Xlr3b operates downstream of or in conjunction with this pathway, its inhibition by LY294002 could result in decreased Xlr3b activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that can suppress cell growth and proliferation. By inhibiting mTOR, a kinase that might be upstream of Xlr3b's activity, rapamycin could indirectly diminish the functional activity of Xlr3b. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide inhibits protein synthesis by interfering with the translocation step in protein elongation. This could lead to a general decrease in the levels of proteins, including those that are part of the Xlr3b pathway, thus indirectly inhibiting Xlr3b. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK, a kinase involved in the MAPK/ERK pathway. If Xlr3b's function is related to this pathway, inhibiting MEK could reduce Xlr3b activation. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $56.00 $212.00 $764.00 | 24 | |
Nutlin-3 inhibits the interaction between p53 and MDM2, leading to the stabilization and activation of p53. If Xlr3b activity is negatively regulated by p53, then Nutlin-3 could indirectly inhibit Xlr3b by enhancing p53 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of proteins, leading to increased protein levels and potential stress responses. If Xlr3b is regulated by proteasomal degradation, bortezomib could indirectly inhibit its activity by altering protein turnover. | ||||||